Drug Trial Radar · NCT03571256
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
158
Actual
Start
May 31, 2018
Primary completion
Dec 9, 2019
Study completion Dec 9, 2019
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- Collaborators
- Nuvelution TS Pharma, Inc.
- First posted
- Jun 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Standard placebo-controlled, double-blind study design (TEV-50717 \[low dose and high dose\] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the tics in participants with TS.
Conditions
- Tourette Syndrome
Interventions
TEV-50717Drug
6-, 9-, 12-, 15-, and 18 mg oral tablets
PlaceboDrug
Placebo matched to TEV-50717 tablets will be taken BID.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the TTS of the YGTSS at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated ParticipantsTime frame: Baseline, Week 8
Locations
56 sites in 10 countries. Site status is shown where the registry gives one.
Teva Investigational Site 060-0160
Gainesville, Florida
Teva Investigational Site 060-0166
Gulf Breeze, Florida
Teva Investigational Site 060-0161
Miami, Florida
Teva Investigational Site 060-0151
Orlando, Florida
Teva Investigational Site 060-0153
Orlando, Florida
Teva Investigational Site 060-0168
Atlanta, Georgia
Teva Investigational Site 060-0155
Chicago, Illinois
Teva Investigational Site 060-0164
Chicago, Illinois
Teva Investigational Site 060-0152
Indianapolis, Indiana
Teva Investigational Site 060-0158
Louisville, Kentucky
Teva Investigational Site 060-0167
Rockville, Maryland
Teva Investigational Site 060-0165
Ann Arbor, Michigan
Teva Investigational Site 060-0170
Bridgeton, Missouri
Teva Investigational Site 060-0154
New York, New York
Teva Investigational Site 060-0169
Charleston, South Carolina
Teva Investigational Site 060-0157
Memphis, Tennessee
Teva Investigational Site 060-0156
Nashville, Tennessee
Teva Investigational Site 060-0163
Fort Worth, Texas
Teva Investigational Site 060-0162
Everett, Washington
Teva Investigational Site 060-1407
Buenos Aires, Argentina
Teva Investigational Site 060-1401
Buenos Aires, Argentina
Teva Investigational Site 060-1402
Buenos Aires, Argentina
Teva Investigational Site 060-1403
La Plata, Argentina
Teva Investigational Site 060-1404
Mendoza, Argentina
Teva Investigational Site 060-1802
Liverpool, Australia
Teva Investigational Site 060-1801
Parkville, Australia
Teva Investigational Site 060-1503
Bello, Colombia
Teva Investigational Site 060-1501
Medellín, Colombia
Teva Investigational Site 060-1506
Medellín, Colombia
Teva Investigational Site 060-1504
Pereira, Colombia
Teva Investigational Site 060-0901
Budapest, Hungary
Teva Investigational Site 060-0902
Szeged, Hungary
Teva Investigational Site 060-1005
Cagliari, Italy
Teva Investigational Site 060-1001
Catania, Italy
Teva Investigational Site 060-1003
Naples, Italy
Teva Investigational Site 060-1004
Rome, Italy
Teva Investigational Site 060-1601
Culiacán, Mexico
Teva Investigational Site 060-1603
León, Mexico
Teva Investigational Site 060-1602
Monterrey, Mexico
Teva Investigational Site 060-1604
Monterrey, Mexico
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.